'The most exciting company in Australia': The ASX stock up 179% in 6 months

This outfit remains a bargain despite almost tripling its share price since June, say experts.

| More on:
A doctor sits with a patient and uses a pen to point to certain parts of her mammogram scan

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

If an ASX biotech stock has almost tripled in 6 months but the valuation still remains "cheap", then you would be careless to not at least consider adding it to your portfolio.

According to Frazis Capital portfolio manager Michael Frazis, Sydney company Clarity Pharmaceuticals Ltd (ASX: CU6) has been "on a bit of a tear".

"This is the most exciting company I've come across in Australia lately," he said in a memo to clients.

"Clarity has been steadily releasing data from patients treated with their copper therapies with late stage prostate cancer."

That data has apparently been favourable, causing the share price to rocket 179% from its 52-week low in late June.

Biotechs snapped up for billions with early data

Frazis said that mergers and acquisitions activity in the global biotechnology industry has been "intense".

And those transactions provide some clues as to how undervalued Clarity Pharmaceuticals still is, despite the spectacular rise the last few months.

"If their data continues to hold, this is still early days, and it remains a fraction of the value of recent acquisitions in the space with early stage data."

Just last week US$100 billion giant Bristol-Myers Squibb Co (NYSE: BMY) acquired RayzeBio Inc (NASDAQ: RYZB) for US$4.1 billion, on the back of early data for its gastroenteropancreatic neuroendocrine tumour therapy and the start of a phase III trial.

"And Novartis AG (SWX: NOVN) paid US$2 billion for Endocyte in late 2018 with only Phase II data," said Frazis.

"This has proved a big winner, with first year revenues for their first product Pluvicto forecast at over US$1 billion."

This week Eli Lilly And Co (NYSE: LLY) completed its acquisition of Point Biopharma Global Inc (NASDAQ: PNT) for US$1.4 billion with only phase II data.

This is why Frazis believes that the Clarity share price remains a bargain despite the massive appreciation this year.

"In a space where companies with promising data are being acquired for billions of dollars, and Clarity's early indications look best-in-class, the company's post-runup US$340 million valuation looks cheap."

'Double or even triple industry revenues'

Prostate cancer will be "a large market", according to Frazis.

"The trend is towards increased monitoring and — where possible — fewer surgeries and hormone therapy, which involves the unwelcome side effects of incontinence, impotence, low testosterone and depression."

Currently the biotechs are treating "heavily pretreated patients", but in the longer run their solutions could be applied more proactively.

"The hope is that these targeted treatments, with their milder side effects, will move further up the treatment timeline, which could double or even triple industry revenues," said Frazis.

"This will take time, given the high hurdle for changing standard-of-care, but is looking more likely than ever today."

In the short term, both incidence and diagnosis is increasing for prostate cancer, which will keep feeding Clarity's valuation.

While the biotech stock is sparsely covered, at least Jefferies and Wilsons analysts agree with Frazis. Both teams rate Clarity Pharmaceuticals as a strong buy, as shown in CMC Invest.

Wondering where you should invest $1,000 right now?

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for over ten years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes could be the 'five best ASX stocks' for investors to buy right now. We believe these stocks are trading at attractive prices and Scott thinks they could be great buys right now...

See The 5 Stocks *Returns as of 30 April 2025

Motley Fool contributor Tony Yoo has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Bristol Myers Squibb and Point Biopharma Global. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Should I buy the dip on CSL shares?

A leading fund manager gives his verdict on the growth prospects for CSL shares.

Read more »

A woman relaxes on a yellow couch with a book and cuppa, and looks pensively away as she contemplates the joy of earning passive income.
Healthcare Shares

NIB shares have soared 24% this year. Does Macquarie expect this to continue?

Will this private health insurer continue to deliver big returns? Let's find out.

Read more »

Woman presenting financial report on large screen in conference room.
Healthcare Shares

Up nearly 30% in a year, should I buy Fisher & Paykel shares before its earnings result?

Will the ASX 200 healthcare stock continue to outperform?

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

CSL shares among most expensive on ASX. Is now a good time to buy?

Analysts predict CSL share price growth will keep on coming.

Read more »

A man looking at his laptop and thinking.
Healthcare Shares

Should you buy the dip in the ResMed share price?

Let's see what one leading broker is saying following yesterday's pullback.

Read more »

A woman puts up her hands and looks confused while sitting at her computer.
Healthcare Shares

Down 5%: What's going on with the ResMed share price?

Let's see what has spooked investors today and caused them to push the sell button.

Read more »

Beautiful young woman drinking fresh orange juice in kitchen.
Healthcare Shares

Guess which ASX 300 stock is jumping 11% on big news

This stock is having a day to remember on Thursday. But why?

Read more »

A group of medical researchers stands side by side with each other wearing white coats in their research laboratory with scientific equipment in the background.
Healthcare Shares

Trump executive order to hit these 3 ASX pharmaceutical stocks

Donald Trump’s new executive order caused these 3 ASX pharmaceutical stocks to crash on Monday.

Read more »